Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Hepatoblastoma Clinical Trials

A listing of Hepatoblastoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (30) clinical trials

Radiolabeled Glass Beads (TheraSphere ) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

OBJECTIVES: - Provide supervised access to yttrium-90 glass microspheres (TheraSphere®) for patients with unresectable hepatocellular carcinoma. - Determine the response in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion of yttrium-90 glass microspheres. - Determine the toxic effects and adverse experiences associated with this therapy in these patients. ...

Phase

Phlebotomy to Prevent Blood Loss in Major Hepatic Resections

Major liver resection is associated with significant intraoperative blood loss. Blood loss in elective liver surgery is a key determinant of perioperative morbidity and mortality, as well as possibly long-term oncologic outcome. Whole blood phlebotomy is a simple intervention, whose aim is to decrease the central venous pressure yielding a ...

Phase N/A

HAI Via Interventionally Implanted Port Catheter Systems

Inclusion criteria: - histologically confirmed hepatic cancer without symptomatic extrahepatic manifestation. - non-resectable disease or hepatic resection or ablation in between the past 8 weeks. - measurable disease (at least before hepatic resection) - Karnofsky performance status => 70%, or ECOG status 0-2 - >18 years of age - life ...

Phase

Biomarkers and Radiation Side Effects in Patients Undergoing Radiation Therapy for Gastrointestinal Cancer

OBJECTIVES: Primary - Determine if tumor-specific DNA mutations and aberrant DNA methylation can be detected in the serum, urine, or stool at the time of diagnosis in patients undergoing radiotherapy for gastrointestinal malignancies. - Determine if changes in mutational status at follow up are associated with disease persistence, recurrence, or ...

Phase N/A

Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery

OBJECTIVES: Primary - Determine the response rate in patients with unresectable, nonmetastatic hepatocellular carcinoma treated with neoadjuvant oxaliplatin, doxorubicin hydrochloride, fluorouracil, and recombinant interferon alfa-2b. Secondary - Determine the overall survival of patients treated with this regimen. - Determine the progression-free survival of patients treated with this regimen. - Determine ...

Phase

A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.

Protocol Objectives include: - Determine the proportion of patients with HCC in whom the treatment plan can be completed - Evaluate the response to therapy - Evaluate toxicities and adverse experiences associated with TheraSphere treatment - Evaluate survival time

Phase

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

Significant advances have been made in recent years in the treatment of solid tumors of childhood. However, much of the improvement in survival has been made in low stage and localized disease. Of significance is the fact that the improvements have come in up-front remission rates without translation into significantly ...

Phase

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

INT230-6 is comprised of a 3 agents in a fixed ratio - a cell permeation enhancer and two, potent anti-cancer payloads (cisplatin and vinblastine sulfate). The penetration enhancer facilitates dispersion of the two drugs throughout injected tumors and enables increased diffusion into cancer cells. (Nonclinical safety studies showed no findings ...

Phase

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma, esophageal cancer and malignant melanoma. Patients must be positive for HLA-A*02:01 or HLA-A*02:06 and the ...

Phase

TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma

This protocol provides TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. Patients with hepatocellular carcinoma will be evaluated for eligibility for this treatment with the following: physical examination, medical history, blood tests requiring approximately 2 tablespoons of blood, EKG, CT or MR of chest to ...

Phase N/A